Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer

Pancreatic cancer is characterized by an immunosuppressive tumor microenvironment (TME) with a profound immune infiltrate populated by a significant number of myeloid-derived suppressor cells (MDSCs). MDSCs have been increasingly recognized for their role in immune evasion and cancer progression as well as their potential as a target for immunotherapy. However, not much is known about the mechanisms regulating their behavior and function in the pancreatic TME. Here we report that pancreatic adenocarcinoma up-regulated factor (PAUF), a soluble protein involved in pancreatic tumorigenesis and metastasis, plays a role as an enhancer of tumor-infiltrating MDSC and its functional activity. We show that PAUF enhanced the accumulation of MDSCs in the spleen and tumor tissues of PAUF-overexpressing tumor cell-injected mice. In addition, PAUF was found to enhance the immunosuppressive function of MDSCs via the TLR4-mediated signaling pathway, which was demonstrated by PAUF-induced increased levels of arginase, nitric oxide (NO), and reactive oxygen species (ROS). The role of PAUF in modulating the functional properties of MDSCs was further demonstrated by the use of a PAUF-neutralizing antibody that caused a decreased number of tumor-infiltrating MDSCs and reduced MDSC immunosuppressive activity. The observations made in mice were confirmed in human pancreatic cancer patient-derived MDSCs, supporting the clinical relevance of our findings. Collectively, we conclude that the PAUF is a powerful and multifunctional promoter of tumor growth through increase and functional activation of MDSCs, suggesting therapeutic potential for targeting PAUF in pancreatic cancers.

[1]  C. Slingluff,et al.  From bench to bedside a comprehensive review of pancreatic cancer immunotherapy , 2016, Journal of Immunotherapy for Cancer.

[2]  R. Qin,et al.  Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. , 2016, Hepatobiliary & pancreatic diseases international : HBPD INT.

[3]  Umar Mahmood,et al.  Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. , 2015, Cancer cell.

[4]  Xiaojuan Chen,et al.  CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancer , 2015, Oncotarget.

[5]  Young Seob Kim,et al.  Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4 , 2015, Oncotarget.

[6]  K. Xie,et al.  Pancreatic cancer stromal biology and therapy , 2015, Genes & diseases.

[7]  Zachary B. Abrams,et al.  Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease , 2015, Cancer Immunology, Immunotherapy.

[8]  R. Ramchandran,et al.  Lipopolysaccharide (LPS)-mediated Angiopoietin-2-dependent Autocrine Angiogenesis Is Regulated by NADPH Oxidase 2 (Nox2) in Human Pulmonary Microvascular Endothelial Cells* , 2015, The Journal of Biological Chemistry.

[9]  K. Guo,et al.  Interaction between pancreatic cancer cells and tumor‐associated macrophages promotes the invasion of pancreatic cancer cells and the differentiation and migration of macrophages , 2014, IUBMB life.

[10]  Young Woo Park,et al.  A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis. , 2014, Biochemical and biophysical research communications.

[11]  M. Lesina,et al.  The immune network in pancreatic cancer development and progression , 2014, Oncogene.

[12]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[13]  Amber J. Giles,et al.  Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy , 2014, Science Translational Medicine.

[14]  D. Alizadeh,et al.  Chemotherapeutic targeting of cancer-induced immunosuppressive cells. , 2014, Cancer research.

[15]  P. Greenberg,et al.  Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity , 2014, Gut.

[16]  B. Ammori,et al.  Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients , 2014, Journal of immunology research.

[17]  S. Dey,et al.  CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. , 2013, Cancer cell.

[18]  M. Hollingsworth,et al.  Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer , 2013, Cancer Immunology, Immunotherapy.

[19]  M. Falconi,et al.  Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study , 2013, PloS one.

[20]  A. Viola,et al.  The pros and cons of chemokines in tumor immunology. , 2012, Trends in immunology.

[21]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[22]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[23]  K. Odunsi,et al.  PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. , 2011, Cancer research.

[24]  L. Coussens,et al.  Immune microenvironments in solid tumors: new targets for therapy. , 2011, Genes & development.

[25]  D. Schadendorf,et al.  Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model , 2011, Proceedings of the National Academy of Sciences.

[26]  T. Wynn,et al.  Regulation of Macrophage Arginase Expression and Tumor Growth by the Ron Receptor Tyrosine Kinase , 2011, The Journal of Immunology.

[27]  S. S. Koh,et al.  PAUF promotes adhesiveness of pancreatic cancer cells by modulating focal adhesion kinase , 2011, Experimental & Molecular Medicine.

[28]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[29]  S. S. Koh,et al.  Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the expression of β-catenin, leading to a rapid proliferation of pancreatic cells , 2011, Experimental & Molecular Medicine.

[30]  Young Woo Park,et al.  Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation , 2011, Oncogene.

[31]  S. Bicciato,et al.  Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. , 2010, Immunity.

[32]  Yan Zhao,et al.  Pancreatic Stellate Cells Increase the Invasion of Human Pancreatic Cancer Cells through the Stromal Cell-Derived Factor-1/CXCR4 Axis , 2010, Pancreatology.

[33]  S. Ostrand-Rosenberg.  Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity , 2010, Cancer Immunology, Immunotherapy.

[34]  Margarida Saraiva,et al.  The regulation of IL-10 production by immune cells , 2010, Nature Reviews Immunology.

[35]  S. S. Koh,et al.  PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression , 2010, Oncogene.

[36]  M. Manns,et al.  Increase in frequency of myeloid‐derived suppressor cells in mice with spontaneous pancreatic carcinoma , 2009, Immunology.

[37]  Christopher Bird,et al.  Real-time, label-free monitoring of cellular invasion and migration with the xCELLigence system , 2009 .

[38]  S. S. Koh,et al.  Pancreatic adenocarcinoma up‐regulated factor (PAUF), a novel up‐regulated secretory protein in pancreatic ductal adenocarcinoma , 2009, Cancer science.

[39]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[40]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[41]  Michelle Collazo,et al.  Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.

[42]  D. Foell,et al.  Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.

[43]  W. Nacken,et al.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.

[44]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[45]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[46]  Jingxia Li,et al.  A JNK1/AP-1–Dependent, COX-2 Induction Is Implicated in 12-O-Tetradecanoylphorbol-13-Acetate–Induced Cell Transformation through Regulating Cell Cycle Progression , 2008, Molecular Cancer Research.

[47]  J. Benovic,et al.  Regulation of CXCR4 signaling. , 2007, Biochimica et biophysica acta.

[48]  T. Kipps,et al.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.

[49]  D. Gabrilovich,et al.  Tumor Associated CD8+ T-Cell Tolerance Induced by Bone Marrow Derived Immature Myeloid Cells , 2005 .

[50]  D. Gabrilovich,et al.  Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells1 , 2005, The Journal of Immunology.

[51]  D. Linehan,et al.  CD25+CD4+ regulatory T-cells in cancer , 2005, Immunologic research.

[52]  U. Förstermann,et al.  Regulation of the Expression of Inducible Nitric Oxide Synthase , 2003, Biological chemistry.

[53]  Gordon Stamp,et al.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.

[54]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[55]  V. Calvert,et al.  Role of Tyrosine Phosphorylation in Ligand-independent Sequestration of CXCR4 in Human Primary Monocytes-Macrophages* , 2001, The Journal of Biological Chemistry.

[56]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[57]  Gideon Rechavi,et al.  A Possible Role for CXCR4 and Its Ligand, the CXC Chemokine Stromal Cell-Derived Factor-1, in the Development of Bone Marrow Metastases in Neuroblastoma1 , 2001, The Journal of Immunology.

[58]  D. Gabrilovich,et al.  Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells1 , 2001, The Journal of Immunology.

[59]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[60]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[61]  Shu-Hsia Chen,et al.  Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 , 2000, The Journal of Immunology.

[62]  S. Ostrand-Rosenberg,et al.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. , 2015, Advances in cancer research.

[63]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[64]  S. S. Koh,et al.  Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability , 2013, Oncogene.

[65]  V. Bronte,et al.  Myeloid-derived suppressor cells in cancer , 2008 .